Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

23.73USD
12:27pm EDT
Change (% chg)

$-0.04 (-0.17%)
Prev Close
$23.77
Open
$23.79
Day's High
$24.01
Day's Low
$23.49
Volume
75,655
Avg. Vol
554,080
52-wk High
$24.18
52-wk Low
$7.22

Select another date:

Thu, May 3 2018

BRIEF-Spectrum Pharmaceuticals Reports Q1 Non-GAAP Loss Per Share $0.15

* SPECTRUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

* SPECTRUM PHARMACEUTICALS ENTERS INTO A NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

BRIEF-Shrotriya May Sell Up To 1 Mln Shares Of Spectrum Pharmaceuticals' Common Stock

* RAJESH C. SHROTRIYA - SHROTRIYA MAY SELL UP TO 1 MILLION SHARES OF SPECTRUM PHARMACEUTICALS' COMMON STOCK BETWEEN MARCH 26 AND JUNE 29 - SEC FILING‍​ Source text: (https://bit.ly/2pKokJc) Further company coverage:

BRIEF-Spectrum Pharma Q4 Loss Per Share $0.29

* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Spectrum Pharmaceuticals Announces Appointment Of William Ashton To Its Board

* SPECTRUM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF WILLIAM L. ASHTON TO ITS BOARD OF DIRECTORS

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

Select another date: